Transforming the performance of medicines through particle engineering
Our proprietary mSAS® supercritical fluid platform enables us to engineer particles of small molecule and biomolecule therapeutics with high levels of precision, to improve bioavailability, enhance stability, and to optimise delivery.
Our Mission
CrystecPharma is a global leading pharmaceutical technology company focused on transforming the performance of medicines.
We design particles and processes with the patient in mind ensuring that an optimal profile can be achieved from existing and new therapeutics.
Our focus is on simplicity of product formulation, accelerated development, and designing highly efficient manufacturing processes that contribute to a greener planet.
Explore our Technology Solutions
Improving Dissolution
- More details
Optimised Inhaled Therapies
- More details
Enhancing Stability
- More details
Simplified Formulations
Formulation is often a complex, multi-step process, adding considerable time and cost to development. The mSAS® process involves a single step, and enables design of particles which contain all the components required for a medicine to perform, reducing the need for downstream processing.
- More details
Biomolecule Processing
Biotherapeutics such as peptides, proteins, antibodies and oligonucleotides are often delicate and easily damaged. mSAS® provides a gentle way to process biomolecules as free-flowing powders, retaining high levels of activity, reducing cold chain and enabling easier reconstitution.
- More details
Natural Products
Natural products are often highly complex and conventional approaches to their extraction, purification and formulation can be inefficient and often result in a poor-quality product. mSAS® simplifies production of natural products, allowing fine tuning of the components of a medicine and improvements in quality and consistency.
- More details
Green Manufacturing
Improvements in human health should not come at a cost to the planet, yet traditional approaches to medicine manufacturing carry a high environmental burden. mSAS® enables the production of medicines with lower waste, reduced emissions, using less solvent, and greatly improved energy efficiency.
- More details
Intellectual Property
Innovation in medicine development often requires robust protection of intellectual property (IP). The mSAS® process provides numerous opportunities to enhance IP, whether through novel solid-state forms, improved formulations, or new routes of delivery.
- More details
mSAS® Technology
The Crystec team have pioneered the development of mSAS®, a modified Supercritical Anti-Solvent process. mSAS® is a powerful technology for engineering particles to improve the bioavailability, stability, and delivery of small molecule and large molecule therapeutics.
This unique platform enables the size and shape of particles to be finely tuned. Where required, more than one drug can be combined in a particle, or excipients incorporated in the particle to further enhance performance and reduce manufacturing complexity. We design particles with the medicine in mind, hence Performance in Every Particle®.
In the mSAS® process, a drug molecule and any other required components are dissolved and introduced into a vessel together with a stream of supercritical carbon dioxide which rapidly extracts the solvent, enabling the drug to be precipitated under precise, tuneable conditions. Among the many strengths of the mSAS® platform are the ability to manipulate the crystallinity of small molecule therapeutics and to generate free-flowing powders of biomolecules whilst retaining high levels of activity.
mSAS® Technology
in Action
AI Accelerated Product Development
Discover our Latest News
December 20, 2023
November 29, 2023
October 23, 2023
Follow us on LinkedIn to stay up to date with news, articles, updates and more
Schedule a Meeting
Contact our team today to see how CrystecPharma’s technology and expertise could revolutionize your pharmaceutical program.
